The Effect of Metformin on the Metabolic Abnormalities Associated With Upper-Body Fat Distribution. BIGPRO Study Group

OBJECTIVE The constellation of anomalies associated with insulin resistance is a plausible additional cause of ischemic cardiovascular disease and of NIDDM. To test this hypothesis in a primary prevention trial, the effects of metformin as a potential candidate for intervention in the insulin resistance syndrome (IRS) were evaluated in 324 middle-aged subjects with upper-body obesity. RESEARCH DESIGN AND METHODS Trial patients were selected on the basis of a high waist-to-hip ratio. They were randomly allocated to receive either metformin or placebo, following a double-blind procedure. After 1 year of treatment, the main clinical and biological parameters of the IRS were assessed and their evolution compared between treatment groups. RESULTS Compared with placebo, metformin induced a significant weight loss, a better maintenance of fasting blood glucose, total and LDL cholesterol levels, and a greater decrease of fasting plasma insulin concentration. Moreover, tissue-type plasminogen activator antigen, a marker of fibrinolytic impairment, showed a significant decrease under metformin. By contrast, metformin treatment had no significant effect on blood pressure or serum triglyceride and HDL cholesterol concentrations. The main side effect of metformin was diarrhea. CONCLUSIONS The BIGuanides and Prevention of Risks in Obesity (BIGPRO1) results suggest that metformin would be a suitable candidate for long-term intervention for the prevention of diabetes but that its use in a trial of primary prevention of cardiovascular diseases requires either a reevaluation of its properties toward the most potentially atherogenic anomalies of the IRS or a better definition of the target population.

[1]  K. Bjerve,et al.  Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease , 1996, Journal of internal medicine.

[2]  P. J. Berry United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years , 1995, BMJ.

[3]  U. Smith,et al.  Metformin and metoprolol CR treatment in non‐obese men , 1994, Journal of internal medicine.

[4]  R. Marfella,et al.  Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women , 1993, Diabetes Care.

[5]  J. Yudkin,et al.  Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.

[6]  L. Groop,et al.  Metformin Normalizes Nonoxidative Glucose Metabolism in Insulin-Resistant Normoglycemic First-Degree Relatives of Patients With NIDDM , 1992, Diabetes.

[7]  A. Kissebah Insulin resistance in visceral obesity. , 1991, International journal of obesity.

[8]  P. Declerck,et al.  Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. , 1991, Thrombosis research.

[9]  J. Schneider Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. , 1991, Diabete & metabolisme.

[10]  M. Austin Plasma triglyceride and coronary heart disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  P. Björntorp "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. , 1990, Arteriosclerosis.

[12]  P. Winocour,et al.  Placebo‐controlled Trial of the Effects of Guar Gum and Metformin on Fasting Blood Glucose and Serum Lipids in Obese, Type 2 Diabetic Patients , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[13]  G. Reaven,et al.  Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients , 1990, Diabetes Care.

[14]  M. Uusitupa,et al.  Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. , 1990, Annals of medicine.

[15]  N. Kaplan The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[16]  D. W. Foster Insulin resistance--a secret killer? , 1989, The New England journal of medicine.

[17]  H. Beck-Nielsen,et al.  Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. , 1989, Acta endocrinologica.

[18]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[19]  B. Risberg,et al.  Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. , 1988, Thrombosis research.

[20]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[21]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[22]  M. Alessi,et al.  Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects , 1987, Thrombosis and Haemostasis.

[23]  J. Jaspan,et al.  Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes , 1987, Diabetes.

[24]  D. Collen,et al.  Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA , 1985, Thrombosis and Haemostasis.

[25]  M. Vranic,et al.  Hyperinsulinemia and hypertriglyceridemia, a vicious cycle with atherogenic potential. , 1982, International journal of obesity.